Oncoinvent ASA (7BG)

Profile

https://www.oncoinvent.com

Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for direct intraperitoneal administration after surgical resection of macroscopic tumors, Radspherin targets micro-metastases in body cavities, particularly for peritoneal carcinomatosis from ovarian and colorectal cancers. Key features include high-power alpha radiation with short range and half-life, slow-degrading microparticles for regional retention of effective radiation dose, and avoidance of biological targeting complexities. The company operates a state-of-the-art GMP-certified manufacturing facility in Oslo for producing Radspherin to support multi-center clinical trials across Europe and North America. Ongoing clinical programs include completed Phase 1 and Phase 1/2a trials, and a randomized Phase 2 trial in the US, UK, and Europe. Founded in 2010 and headquartered in Oslo, Norway, Oncoinvent ASA plays a role in advancing targeted radiotherapies within the oncology sector.